Invention Grant
US09046532B2 Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin 有权
通过确定降钙素原的水平,对患有原发性非传染性疾病的患者进行抗生素治疗的风险评估

  • Patent Title: Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin
  • Patent Title (中): 通过确定降钙素原的水平,对患有原发性非传染性疾病的患者进行抗生素治疗的风险评估
  • Application No.: US13264252
    Application Date: 2010-04-14
  • Publication No.: US09046532B2
    Publication Date: 2015-06-02
  • Inventor: Andreas BergmannJoachim Struck
  • Applicant: Andreas BergmannJoachim Struck
  • Applicant Address: DE Hennigsdorf
  • Assignee: B.R.A.H.M.S GMBH
  • Current Assignee: B.R.A.H.M.S GMBH
  • Current Assignee Address: DE Hennigsdorf
  • Agency: Millen, White, Zelano & Branigan, P.C.
  • Priority: EP09157886 20090414
  • International Application: PCT/EP2010/002279 WO 20100414
  • International Announcement: WO2010/118855 WO 20101021
  • Main IPC: G01N33/00
  • IPC: G01N33/00 G01N33/74
Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin
Abstract:
A diagnostic method for the identification of a subject suffering from a primary non-infectious disease having an increased risk of an adverse outcome potentially being induced by the administration of an antibiotic to said subject comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having a length of at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk induced by the administration of an antibiotic, as well as a kit for performing the method and methods of treatment based thereon.
Information query
Patent Agency Ranking
0/0